* Transkaryotic Therapies Inc., of Cambridge, Mass., started enrolling patients in a Phase I study of a gene-therapy treatment for hemophilia. The study, which will take place at the Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School, in Cambridge, Mass., is expected to last up to three years, including a two-year follow-up period after treatment. The company's nonviral, gene-therapy technology is based on genetically modifying a patient's cells to produce and deliver therapeutic proteins for an extended period of time.